Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study
Crossref DOI link: https://doi.org/10.1007/s00228-016-2143-9
Published Online: 2016-10-15
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gueret, P.
Combe, S.
Krezel, C.
Fuseau, E.
van Giersbergen, P. L. M.
Petitou, M.
Neuhart, E.
Funding for this research was provided by:
Endotis Pharma, Romainville, France
License valid from 2016-10-15